ArticleThe Journal of organic chemistry2012
Total synthesis of a cyclic adenosine 5'-diphosphate ribose receptor agonist.
Article in The Journal of organic chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Small Molecule CD38 Inhibitors: Synthesis of 8-Amino-Molecules (Basel, Switzerland) · 2021Article
- Roles of NADMolecules (Basel, Switzerland) · 2020Review
- Synthesis of Phospho-Amino Acid Analogues as Tissue Adhesive Cement Additives.ACS central science · 2020Article
- New Linear Precursors of cIDPR Derivatives as Stable Analogs of cADPR: A Potent Second Messenger with CaMarine drugs · 2019Article
- Synthetic cADPR analogues may form only one of two possible conformational diastereoisomers.Scientific reports · 2018Article
- Adenosine: Synthetic Methods of Its Derivatives and Antitumor Activity.Mini reviews in medicinal chemistry · 2018Review
- Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid "L-cyclic inosine 5'-diphosphate ribose".Scientific reports · 2017Article
- Synthesis of cyclic N (1)-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells.Beilstein journal of organic chemistry · 2015Article
- Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.Journal of medicinal chemistry · 2014Article
- 'Click cyclic ADP-ribose': a neutral second messenger mimic.Chemical communications (Cambridge, England) · 2014Article
- Design and synthesis of cyclic ADP-4-thioribose as a stable equivalent of cyclic ADP-ribose, a calcium ion-mobilizing second messenger.Angewandte Chemie (International ed. in English) · 2013Article
- Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose.Messenger (Los Angeles, Calif. : Print)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Stable cyclic adenosine 5'-diphosphate ribose (cADPR) analogues are chemical biology tools that can probe the Ca(2+) release mechanism and structure-activity relationships of this emerging potent second messenger. However, analogues with an intact "northern" ribose have been inaccessible due to the difficulty of generating the sensitive N1-ribosyl link. We report the first total synthesis of the membrane permeant, hydrolytically stable, cADPR receptor agonist 8-Br-N1-cIDPR via regio- and stereoselective N1-ribosylation of protected 8-bromoinosine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.